 - Patients who were newly diagnosed as chronic phase chronic myelogenous leukemia, were enrolled to IDEAL study A Phase IV Study to Evaluate Efficacy and Safety of ImatinibGlinib 600mgday Depending on Early Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase, NCT02204722 